ERBB2 and breast carcinoma: Tucatinib is prescribed in conjunction with Trastuzumab and Capecitabine for the management of advanced, non-surgically resectable, or metastatic HER2-positive breast cancer in adult patients, encompassing those with brain metastases, who have undergone one or multiple prior regimens involving anti-HER2 therapies within the metastatic context.